(Circulation. 1995;91:1354-1362.)
© 1995 American Heart Association, Inc.
Articles |
Comparative Real-Time Effects on Platelet Adhesion and Aggregation Under Flowing Conditions of In Vivo Aspirin, Heparin, and Monoclonal Antibody Fragment Against Glycoprotein IIb-IIIa
From the Cox Laboratory for Biomedical Engineering, Rice University, Houston, Tex (N.A.T, J.L.M., L.V.M.); the Department of Medicine, Baylor College of Medicine, Houston, Tex (J.L.M., S.G.K., A.I.S., N.S.K.); and Centocor, Inc, Malvern, Pa (R.J.).
Correspondence to Joel L. Moake, MD, Cox Laboratory for Biomedical Engineering, Rice University, PO Box 1892, Houston, TX 77251.
Background A real-time in vitro system of human platelet thrombosis under arterylike flowing conditions similar to those produced in vivo by angioplasty would be useful for the evaluation of potential antiarterial thrombotic agents in association with in vivo trials. Aspirin, heparin, and the chimeric monoclonal antibody antigen-binding fragment 7E3 (c7E3 Fab) directed against platelet glycoprotein (GP) IIb-IIIa have been used in attempts to delay or prevent thrombotic reocclusion of coronary arteries after angioplasty. We compared the effects of these agents administered in vivo on GPIb-mediated platelet adhesion to von Willebrand factor (vWF)/collagen type I (as in atherosclerotic subendothelium) and on subsequent GPIIb-IIIa–fibrinogen/vWF–mediated platelet aggregation under flowing conditions analogous to those in constricted coronary arteries.
Methods and Results Citrated whole blood containing mepacrine-labeled platelets from patients and healthy donors was perfused for 1 minute at an abnormally elevated shear rate of 1500 seconds-1 (arterial wall shear stress of 50 to 60 dynes/cm2) at 37°C over collagen I/vWF. The number of adherent fluorescent platelets was quantified every 15 seconds with a low-light-level video camera and epifluorescent microscopy. After 5 healthy donors had ingested 975 mg aspirin, platelet adhesion was unaffected in the aspirin-treated blood compared with the control blood in all experiments (10 of 10), and subsequent aggregation was unchanged in most runs (8 of 10). The blood of 3 aspirin-treated patients undergoing angioplasty was analyzed before and after a 12 000-U heparin injection and 2 minutes, 2 hours, and 24 hours after infusion of 0.25 mg/kg of c7E3 Fab. In these patients, the bolus of heparin did not inhibit either platelet adhesion to collagen I/vWF or subsequent aggregation. In contrast, there was >50% inhibition of platelet aggregation 2 minutes after the infusion of c7E3 Fab in all 3 patients, and inhibition persisted in 2 of the 3 patients at 2 hours and 24 hours after c7E3 Fab.
Conclusions In contrast to aspirin or heparin, the in vivo injection of c7E3 Fab considerably reduces platelet aggregate formation mediated by the binding of fibrinogen, vWF, or some other ligand to platelet GPIIb-IIIa under conditions of abnormally increased shear stress analogous to those in narrowed coronary arteries. Platelet adherence to collagen I/vWF is not affected. This study describes an in vitro model of arterial injury (similar to angioplasty) that uses human blood to compare directly, in real time, the precise relative effects of aspirin, heparin, and c7E3 Fab on platelet adhesion and subsequent aggregation.
Key Words: aspirin • heparin • glycoproteins • von Willebrand factor • blood flow
This article has been cited by other articles:
 |
|
 |
|
  A. O. Spiel, J. C. Gilbert, and B. Jilma Von Willebrand Factor in Cardiovascular Disease: Focus on Acute Coronary Syndromes Circulation, March 18, 2008; 117(11): 1449 - 1459. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. P. Smith, T. A. Alshafie, C. P. Cruz, C.-Y. Fan, A. T. Brown, Y. Wang, J. F. Eidt, and M. M. Moursi Saratin, an Inhibitor of Collagen-Platelet Interaction, Decreases Venous Anastomotic Intimal Hyperplasia in a Canine Dialysis Access Model Vascular and Endovascular Surgery, July 1, 2003; 37(4): 259 - 269. [Abstract] [PDF]
|
|
|
|
 |
|
 D. Patel, H. Vaananen, M. Jirouskova, T. Hoffmann, C. Bodian, and B. S. Coller Dynamics of GPIIb/IIIa-mediated platelet-platelet interactions in platelet adhesion/thrombus formation on collagen in vitro as revealed by videomicroscopy Blood, February 1, 2003; 101(3): 929 - 936. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Wang, R. T. Dorsam, A. Lauver, H. Wang, F. A. Barbera, S. Gibbs, D. Varon, N. Savion, S. M. Friedman, and G. Z. Feuerstein Comparative Analysis of Various Platelet Glycoprotein IIb/IIIa Antagonists on Shear-Induced Platelet Activation and Adhesion J. Pharmacol. Exp. Ther., December 1, 2002; 303(3): 1114 - 1120. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. A. Turner, J. L. Moake, and L. V. McIntire Blockade of adenosine diphosphate receptors P2Y12 and P2Y1 is required to inhibit platelet aggregation in whole blood under flow Blood, December 1, 2001; 98(12): 3340 - 3345. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. P. Abulencia, N. Tien, O. J. T. McCarty, D. Plymire, S. A. Mousa, and K. Konstantopoulos Comparative Antiplatelet Efficacy of a Novel, Nonpeptide GPIIb/IIIa Antagonist (XV454) and Abciximab (c7E3) in Flow Models of Thrombosis Arterioscler Thromb Vasc Biol, January 1, 2001; 21(1): 149 - 156. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. J. Fredrickson, N. A. Turner, N. S. Kleiman, N. Graziadei, K. Maresh, M. A. Mascelli, M. B. Effron, and L. V. McIntire Effects of Abciximab, Ticlopidine, and Combined Abciximab/Ticlopidine Therapy on Platelet and Leukocyte Function in Patients Undergoing Coronary Angioplasty Circulation, March 14, 2000; 101(10): 1122 - 1129. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. J. Fredrickson, J.-F. Dong, L. V. McIntire, and J. A. Lopez Shear-Dependent Rolling on von Willebrand Factor of Mammalian Cells Expressing the Platelet Glycoprotein Ib-IX-V Complex Blood, November 15, 1998; 92(10): 3684 - 3693. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Dangas, J. J. Badimon, B. S. Coller, J. T. Fallon, S. K. Sharma, R. M. Hayes, P. Meraj, J. A. Ambrose, and J. D. Marmur Administration of Abciximab During Percutaneous Coronary Intervention Reduces Both Ex Vivo Platelet Thrombus Formation and Fibrin Deposition : Implications for a Potential Anticoagulant Effect of Abciximab Arterioscler Thromb Vasc Biol, August 1, 1998; 18(8): 1342 - 1349. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Miida, H. Otsuka, A. Tsuchiya, and M. Okada Plasma lipoprotein profiles change significantly during cardiac catheterization Clin. Chem., March 1, 1998; 44(3): 517 - 521. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. D. Berkowitz, R. A. Harrington, M. M. Rund, and J. E. Tcheng Acute Profound Thrombocytopenia After c7E3 Fab (Abciximab) Therapy Circulation, February 18, 1997; 95(4): 809 - 813. [Abstract] [Full Text]
|
|
|
|
|
|
R. R. Makkar, F. Litvack, N. L. Eigler, M. Nakamura, P. A. Ivey, J. S. Forrester, P. K. Shah, R. E. Jordan, and S. Kaul Effects of GP IIb/IIIa Receptor Monoclonal Antibody (7E3), Heparin, and Aspirin in an Ex Vivo Canine Arteriovenous Shunt Model of Stent Thrombosis Circulation, February 18, 1997; 95(4): 1015 - 1021. [Abstract] [Full Text]
|
|
|
|
|
|
P. Andre, B. Arbeille, V. Drouet, P. Hainaud, C. Bal dit Sollier, J. P. Caen, and L. O. Drouet Optimal Antagonism of GPIIb/IIIa Favors Platelet Adhesion by Inhibiting Thrombus Growth : An Ex Vivo Capillary Perfusion Chamber Study in the Guinea Pig Arterioscler Thromb Vasc Biol, January 1, 1996; 16(1): 56 - 63. [Abstract] [Full Text]
|
|
|
|
|
|
K. Konstantopoulos, S. G. Kamat, A. I. Schafer, E. I. Banez, R. Jordan, N. S. Kleiman, and J. D. Hellums Shear-Induced Platelet Aggregation Is Inhibited by In Vivo Infusion of an Anti–Glycoprotein IIb/IIIa Antibody Fragment, c7E3 Fab, in Patients Undergoing Coronary Angioplasty Circulation, March 1, 1995; 91(5): 1427 - 1431. [Abstract] [Full Text]
|
|